About Us

About Servatus

Servatus

Servatus was established in 2012 and began operations in 2013. It is an unlisted public company with headquarters in Coolum, Queensland.

Servatus and international joint-venture partner are building a state-of-the-art production and research facility at Coolum in Queensland to produce medical-grade biopharmaceuticals. The first stage of the facility was completed in 2019.

The company derives its name from St Servatus who was a churchman and diplomat in the fourth century and become Bishop of Tongeren, a city and municipality now in modern-day Belgium. Servatus was invoked by Catholics as a patron saint, with healing powers for a range of ailments, including rheumatism.

Servatus Board

Wayne Finlayson
Executive Director CEO
Wayne Finlayson
Executive Director CEO

Wayne has wide-ranging scientific and commercial corporate experience in the biopharmaceutical and biotechnology sector, stretching over 30 years. His sound knowledge and understanding of the sector internationally include regulatory structures and requirements. During his career, Wayne developed strong skills and experience in the commercialisation of technology and the practical application of science for the creation of sustainable commercial enterprises. He progressed from initial roles focusing on pure science to management positions, including General Manager and Managing Director/CEO.

Positions held include that of Executive Director of Infergene (listed on NASDAQ), with specific responsibility for technology. In 1990, Wayne founded Progen Pharmaceuticals and was Managing Director and CEO. After leaving Progen Pharmaceuticals, he acted as a consultant until 2009, providing technology investment advice to clients. During this period, he also held various contract positions for clients (including large investment firms in the USA), with responsibility for ensuring readiness of investee companies for public listing or other investment.

Wayne holds a BSc (Hons) and a PhD in Organic Chemistry from La Trobe University. After completing his doctorate, he was a post-doctoral Research Fellow for three years at the University of California, Berkeley, in the USA.

Michael Vitale
Non-Executive Chairman
Michael Vitale
Non-Executive Chairman

Michael has extensive commercial, research and teaching experience gained in the USA and Australia. Since 2015, Michael has held the position of Adjunct Professor at the University of Melbourne, where he teaches entrepreneurship to MBA students at the Melbourne Business School and to graduate students at the School of Engineering and the School of Information. He also co-teaches bio-design innovation.

Previously, Michael was a Professor and Director at Monash University, with positions at the Monash Asia-Pacific Centre for Science and Wealth Creation (2006 to 2012) and the Faculty of Information Technology (2008 to 2015). Michael has also held various consultancy, management, commercial and teaching roles in the USA, including Harvard Business School, Prudential Insurance Company of America, and the Ernst & Young Centre for Business Innovation.

Michael has written or contributed to various books and written a large number of professional publications, journal articles, conference papers and case studies.

Michael has acted as a Non-Executive Director in listed and unlisted companies, including ASX-listed Medical Therapies Ltd (now called Cellmid), which he chaired from 2005 to 2008. The company was involved in the commercialisation of anti-inflammatory and anti-cancer therapeutics and entered clinical trials with its first product in February 2008.

Michael holds tertiary qualifications in mathematics from Oakland University in Michigan (BA) and Dartmouth College in New Hampshire (PhD), and an MBA from Harvard Business School.

Mark Williams
Executive Director CFO
Mark Williams
Executive Director CFO

Mark joined the Servatus board as a Non-Executive Director in February 2018 and became an Executive Director (Chief Financial Officer) in July 2018. Mark has had a long career in investment banking, having spent nearly 20 years with Macquarie Bank in Sydney, London and South America. Mark’s broad banking and commercial career includes significant experience in risk, structured lending, governance, commodities & equities markets, and management.

In 2001, Mark set up Macquarie’s off-shore risk function in London. From 2004 to 2014, Mark was based in Sao Paulo, Brazil, initially in charge of the bank’s structured commodity lending and later as office and local country head. Mark, as an Executive Director, was responsible for Macquarie’s Brazilian commodity platform, including management of a number of the bank’s largest global commodity clients.

Mark holds a BComm/LLB (Hons) from The Australian National University.

Hugh Alsop
Board Member
Hugh Alsop
Board Member

Hugh is an accomplished biotech executive with over 22 years of experience in drug development for global markets, pharmaceutical commercialization, international business development and partnering, general management and profit accountability experience. Hugh’s current focus is the founding CEO of Kinoxis Therapeutics Pty Ltd, a new company formed at the beginning of 2018 as spin out from the University of Sydney to develop a range of novel therapeutics for the treatment of substance use disorders and other central nervous system disorders.

More recently, Hugh has been CEO of Hatchtech Pty Ltd, an Australian company developing a novel technology for the control of invertebrate pests. The Company’s lead product is Xeglyze™ Lotion, a next generation prescription head lice product in development that aims to overcome the frustrating, costly and inconvenient cycles of retreatment for head lice infestation currently experienced by children and their parents. In 2015, the company signed a multi-country commercialization agreement for Xeglyze™ with integrated pharmaceutical company Dr. Reddy’s Laboratories (NYSE: RDY). Xeglyze™ has completed clinical development, and a New Drug Application has been filed with the US Food and Drug Administration (FDA).

Hugh has worked in executive positions for a wide spectrum of pharmaceutical and biotechnology companies, including Acrux Limited, Phosphagencis Ltd, Sigma Pharmaceuticals, Mayne Pharma, and Faulding Pharmaceuticals. Whilst at Acrux, Hugh was Director Business Development when in 2010, the company licensed their testosterone product Axiron to Eli Lilly for AUD$335 million in milestones plus royalties.

Hugh has a Bachelor of Science (Honors) in Chemistry from the University of Melbourne and an MBA from the Melbourne Business School.

Company Secretary

Jeremy Martineau
Secretary
Jeremy Martineau
Secretary

Jeremy has a career background in legal practice and lead advisory work. After more than 20 years in legal practice in England and Australia, Jeremy now runs his own consultancy business. Jeremy specialises in company transactional work and has experience in both project management and lead advisory capacities. In Australia, Jeremy worked in legal practice with McCullough Robertson in Brisbane. He subsequently undertook lead advisory work in the corporate finance and investment banking practice of PricewaterhouseCoopers, where he was involved in initiating, structuring and managing a number of transactions (equity investments and company sales) to successful completion.

Jeremy holds an MA (Hons) from Cambridge University and a Diploma in Entrepreneurship Studies and is a member of the Australian Institute of Company Directors.

Former Director/Co-Founder

VALE
Wolf Hanisch, Ph.D
Former Director/Co-Founder
VALE Wolf Hanisch, Ph.D
Former Director/Co-Founder
VALE Jan 1953 - Sep 2019

Doctor of philosophy

University College London

Full Scholarship under the Royal Commission of Exhibition of 1851 Presented at Buckingham Palace by Prince Phillip

Full Member of the New York Academy of Science

Life Member of the American institute of Chemical Engineers

Fellow of The Australian Institute of Company Directors

Servatus Team

Wayne Finlayson
Executive Director CEO
Wayne Finlayson
Executive Director CEO

Wayne has wide-ranging scientific and commercial corporate experience in the biopharmaceutical and biotechnology sector, stretching over 30 years. His sound knowledge and understanding of the sector internationally include regulatory structures and requirements. During his career, Wayne developed strong skills and experience in the commercialisation of technology and the practical application of science for the creation of sustainable commercial enterprises. He progressed from initial roles focusing on pure science to management positions, including General Manager and Managing Director/CEO.

Positions held include that of Executive Director of Infergene (listed on NASDAQ), with specific responsibility for technology. In 1990, Wayne founded Progen Pharmaceuticals and was Managing Director and CEO. After leaving Progen Pharmaceuticals, he acted as a consultant until 2009, providing technology investment advice to clients. During this period, he also held various contract positions for clients (including large investment firms in the USA), with responsibility for ensuring readiness of investee companies for public listing or other investment.

Wayne holds a BSc (Hons) and a PhD in Organic Chemistry from La Trobe University. After completing his doctorate, he was a post-doctoral Research Fellow for three years at the University of California, Berkeley, in the USA.

Mark Williams
Executive Director CFO
Mark Williams
Executive Director CFO

Mark joined the Servatus board as a Non-Executive Director in February 2018 and became an Executive Director (Chief Financial Officer) in July 2018. Mark has had a long career in investment banking, having spent nearly 20 years with Macquarie Bank in Sydney, London and South America. Mark’s broad banking and commercial career includes significant experience in risk, structured lending, governance, commodities & equities markets, and management.

In 2001, Mark set up Macquarie’s off-shore risk function in London. From 2004 to 2014, Mark was based in Sao Paulo, Brazil, initially in charge of the bank’s structured commodity lending and later as office and local country head. Mark, as an Executive Director, was responsible for Macquarie’s Brazilian commodity platform, including management of a number of the bank’s largest global commodity clients.

Mark holds a BComm/LLB (Hons) from The Australian National University.

Samantha Coulson
Clinical Research and Regulatory Affairs
Samantha Coulson
Clinical Research and Regulatory Affairs

Samantha joined Servatus in 2018 to head the Clinical Research Department and manage regulatory scientific affairs. Samantha has a diverse background in both academia and industry. She has extensive experience in designing, leading and collaborating on multidisciplinary research projects; managing product research, innovation and development programs for natural bioactive compounds; and probiotics. She also has extensive experience in designing and conducting human clinical trials; establishing research collaborations with medical specialists and academics; and negotiating research sponsorship with industry partners.

Samantha’s previous positions include managing the Probiotic Development Program at Nutrition Care Pharmaceuticals. During 2014-2016, she held an executive management position within Medlab Pty Ltd, leading the research & development and regulatory departments. Samantha held a postdoctoral research position at the University of Queensland following the completion of her PhD.

Samantha has numerous scientific publications and book chapters in peer-reviewed medical journals and is an invited speaker at national and international medical conferences. She is currently on the editorial board for the Journal of Inflammopharmacology and is peer-reviewer for Dove Medical Press and The Australian Journal of General Practice. She is an Adjunct Senior Research Fellow at the University of Sydney and the University of Sunshine Coast.

Samantha holds a Bachelor of Health Science and Nutrition, Graduate Certificate in Research Commercialisation and a PhD from the University of Queensland’s School of Medicine.

Kylie Ralston
Cell Biologist
Kylie Ralston
Cell Biologist

Kylie joined Servatus in 2018, she is a cell biologist with more than 20 years’ experience across the academic, biotechnology and biopharmaceutical sectors. Before joining Servatus, Kylie worked at Terragen Biotech, an agricultural biotechnology company, co-leading Research and Development.

In 2013, Kylie joined Patheon Biologics (formerly DSM biologics and now part of Thermo Fisher Scientific). She worked in downstream bioprocessing and quality control. In 2007, Kylie joined an early-stage biotechnology company, developing biotherapeutics for autoimmune conditions, working on the lead candidate molecule and expanding its intellectual property coverage.

Previously, Kylie worked for 10 years in research at the University of Newcastle on a variety of projects, including cancer research, inflammation and atherosclerosis.

Kylie holds a BSc (Hons) in biological sciences from the University of Newcastle. She is author and co-author of numerous peer-reviewed publications.

Nicolas Pichon
Bioprocess Engineer
Nicolas Pichon
Bioprocess Engineer

Nicolas joined Servatus in 2018, as a bioprocess engineer. Nicolas’s background is in bioprocess engineering and Research and Development in the biotechnology industry in both Australia and France.

Previously, Nicolas worked as a Downstream Bioprocess Scientist at Patheon Biologics (part of Thermo Fisher Scientific) in Australia. Nicolas is experienced in both fermentation bioprocessing management. He was instrumental in developing an APVMA accredited bacterial laboratory-based and production platform for the development and manufacture of probiotics and enzymes for the feedstock industry.

Nicolas has strong technical knowledge of both the biotechnology industry and the latest bioprocessing technologies.

Nicolas completed a Bioengineering degree at the Sup'Biotech Paris, France in 2012. More recently, Nicolas submitted a PhD in biotechnology at the Australian Institute for Bioengineering and Nanotechnology within the University of Queensland.

Clinical / Advisory Team

Professor Gerald Holtmann
-
Professor Gerald Holtmann
-
MD, PHD, MBA, FRACP, FRCP, FAHMS

Gerald Holtmann is an Academic Gastroenterologist with substantial managerial and leadership experience inside and outside the academic sector.

He is Director of Gastroenterology & Hepatology at the Princess Alexandra Hospital in Queensland and Associate Dean Clinical for the Faculty of Health & Behavioral Sciences and for the Faculty of Medicine at the University of Queensland. In addition, he also serves as Director on the Boards of the West Moreton Hospital and Health Service and the Gallipoli Foundation. Prior to relocation to Brisbane, he completed a 3-year term as CEO and Medical Director of the University Hospital Essen, Germany and has served several years on the Board of this organisation with an annual budget of over $1b. Before that he was Director of the Department of Gastroenterology, Hepatology and General Medicine at the Royal Adelaide Hospital with a joint appointment as Professor of Medicine at the University of Adelaide.

Prof Holtmann has completed his Clinical Training in Medicine and Gastroenterology at the University Hospital Essen, Germany with a fellowship at the Mayo Clinic, Rochester, MN. He is a Fellow of the Royal College of Physicians (London), the Royal Australasian College of Physicians and the Australian Academy of Health and Medical Sciences. In addition to his training in Medicine and Gastroenterology he completed a Master of Business Administration at the University of South Australia and is certified by the German Board of Physicians in Medical Informatics and Biostatistics.

His research in the field of Gastroenterology with a focus on Neurogastroenterology has been published in leading journals including the New England Journal of Medicine, The Lancet, Gut and Gastroenterology and has attracted more than 20,000 citations.

Dr. Peter Nash
-
Dr. Peter Nash
-

School of Medicine
Griffith University
Director
Rheumatology Research Unit
Sunshine Coast

He Serves on the Scientific Advisory Board and the ASMPOC, Australian Rheumatology Association, Steering Committee of GRAPPA and the editorial board of Annals of the Rheumatic Diseases and RMD Open.

Published more than 200 per reviewed articles and 5 book chapters.

Dr Peter Nash is Associate Professor in the Department of Medicine at the University of Queensland, at the school of Medicine, Griffith University, and a Director of the Rheumatology Research Unit on the Sunshine Coast. Dr Nash has Chaired the Professional Affairs Committee and the Therapeutics Committee , and serves on the Scientific Advisory Committee of the Australian Rheumatology Association. He is a former member of the Therapeutics Committee of the Australia and New Zealand Bone and Mineral Society.

Dr Nash and his group at the Rheumatology Research Unit have been involved with pivotal registration clinical trials for all modern targeted biologic therapies and osteoporosis therapies. He has published more than 200 peer-reviewed papers and 5 book chapters. He is on the Scientific Advisory Board and the ASMPOC, Australian Rheumatology Association, Steering Committee of GRAPPA and the editorial board of Annals of the Rheumatic Diseases and RMD Open.

His special interests include metabolic bone disease and novel therapeutics.

Dr Michael Freeman
-
Dr Michael Freeman
-

Dr Michael Freeman is the principal Dermatologist at The Skin Centre, specialising in Cosmetic and Laser Dermatology. Originally graduating from The University of Queensland in 1979, he has more than 30 years’ experience in the medical field. In addition to his position at The Skin Centre, Dr Freeman is the Director of Dermatology at the Gold Coast Hospital and is an Associate Professor of Dermatology at Bond University.

While a Fellow of the Australasian College of Dermatologists, he is also a member of the Skin and Cancer Foundation of Queensland and an international member of the American Academy of Dermatology.

Dr Freeman holds several more credits to his name, including lead investigator in more than a dozen clinical trials, and educator for other Dermatologists in the use of specialised lasers.

Corporate Directory

Corporate Directory

REGISTERED OFFICE

12-14 Lomandra Place
Coolum Beach
QLD 4573
(07) 5357 6830
ABN: 97 160 434 254

DIRECTORS
Dr Wayne Finlayson, Executive Director
Dr Michael Vitale, Non-Executive Chairman
Hugh Alsop, Non-Executive Director
Mr Mark Williams, Executive Director
Company Secretary, Jeremy Martineau

FORMER DIRECTORS
Dr Wolf Hanisch, Co-Founder
vale Jan 1953 - Sep 2019

PATENT ATTORNEY
Davies Collison and Cave
255 Elizabeth St
Sydney NSW 2000

AUDITOR
MGI South Queensland
200 Mary St
Brisbane QLD 4000

LEGAL ATTORNEY
Hillhouse, Burrough
McKeown Lawyers
102 Adelaide St
Brisbane QLD 4000